Alantolactone and isoalantolactone suppress maximal electroshock-induced tonic seizures in mice
More details
Hide details
Isobolographic Analysis Laboratory, Institute of Rural Health in Lublin, Poland
Department of Pathophysiology, Medical University of Lublin in Lublin, Poland
Department of Public Health, Institute of Rural Health in Lublin, Poland
Jarogniew J. Łuszczki   

Institute of Rural Health, Jaczewskiego 2, 20–090 Lublin, Poland tel.: (+48) 81 718 44 88
J Pre Clin Clin Res. 2014;8(1):9–12
Introduction and objective:
The aim of this study was to perform the anticonvulsant screening test to determine whether two sesquiterpene lactones (alantolactone and isoalantolactone) isolated from herbs and medicinal plants offer a distinct protection against maximal electroshock (MES)-induced tonic seizures in mice.

Material and Methods:
The screening test was performed for alantolactone and isoalantolactone administered intraperitoneally in a constant dose of 300 mg/kg at 4 various pretreatment times (i.e., 15, 30, 60 and 120 min.) before the MES test. Tonic hind limb extension (seizure activity) was evoked in adult male albino Swiss mice by a current (sine-wave, 25 mA, 500 V, 50 Hz, 0.2 s stimulus duration) delivered via ear-clip electrodes. Subsequently, the median effective doses (ED50 values) for alantolactone and isoalantolactone were determined in the MES test in mice.

In the screening test, both compounds produced a 37.5% protection against MES-induced tonic seizures in mice, when administered i.p. at 15 min. prior to the MES test. In contrast, alantolactone and isoalantolactone administered i.p. at 30, 60 and 120 min. prior to the test produced no anticonvulsant activity in mice subjected to the MES test. The experimentally-derived ED50 values for alantolactone and isoalantolactone, administered intraperitoneally at 15 min. before the MES test, were 322 (281–369) mg/kg and 336 (285–396) mg/kg, respectively.

Alantolactone and isoalantolactone (2 sesquiterpene lactones) are worth considering as potentially favourable compounds in epileptology, if the results from this study could be extrapolated into clinical settings.

Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem. 2011; 46: 4769–4807.
Koehn FE, Carter GT. The evolving role of natural products in drug discovery. Nat Rev Drug Discov. 2005; 4: 206–220.
Koehn FE, Carter GT. Rediscovering natural products as a source of new drugs. Discov Med. 2005; 5: 159–164.
Christen P, Cuendet M. Plants as a source of therapeutic and health products. Chimia (Aarau). 2012; 66: 320–323.
Zhu HL, Wan JB, Wang YT, Li BC, Xiang C, He J, Li P. Medicinal compounds with antiepileptic/anticonvulsant activities. Epilepsia 2013; doi:10.1111/epi.12463.[in press].
Tagarelli G, Tagarelli A, Liguori M, Piro A. Treating epilepsy in Italy between XIX and XX century. J Ethnopharmacol. 2013; 145: 608–613.
Łuszczki JJ, Głowniak K, Czuczwar SJ. Imperatorin enhances the protective activity of conventional antiepileptic drugs against maximal electroshock-induced seizures in mice. Eur J Pharmacol. 2007; 574: 133–139.
Łuszczki JJ, Głowniak K, Czuczwar SJ. Time-course and dose-response relationships of imperatorin in the mouse maximal electroshock seizure threshold model. Neurosci Res. 2007; 59: 18–22.
Łuszczki JJ, Andres-Mach M, Gleńsk M, Skalicka-Woźniak K. Anticonvulsant effects of four linear furanocoumarins, bergapten, imperatorin, oxypeucedanin, and xanthotoxin, in the mouse maximal electroshock-induced seizure model: a comparative study. Pharmacol Rep. 2010; 62: 1231–1236.
Łuszczki JJ, Wojda E, Raszewski G, Głowniak K, Czuczwar SJ. Influence of imperatorin on the anticonvulsant activity and acute adverse-effect profile of lamotrigine in maximal electroshock-induced seizures and chimney test in mice. Pharmacol Rep. 2008; 60: 566–573.
Łuszczki JJ, Wojda E, Andres-Mach M, Cisowski W, Gleńsk M, Głowniak K, Czuczwar SJ. Anticonvulsant and acute neurotoxic effects of imperatorin, osthole and valproate in the maximal electroshock seizure and chimney tests in mice: a comparative study. Epilepsy Res. 2009; 85: 293–299.
Łuszczki JJ, Włodarczyk M, Gleńsk M, Marzęda E, Durmowicz D, Florek-Łuszczki M. Effects of various naturally occurring compounds (arbutin, borneol, esculetin, esculin, ellagic acid, gallic acid, hesperidine, piperitol, piperonal, quercetin, thymoquinone and ursolic acid) against maximal electroshock-induced seizures in mice. Curr Issues Pharm Med Sci. 2013; 26: 135–139.
Chun J, Choi RJ, Khan S, Lee DS, Kim YC, Nam YJ, Lee DU, Kim YS. Alantolactone suppresses inducible nitric oxide synthase and cyclooxygenase-2 expression by down-regulating NF-κB, MAPK and AP-1 via the MyD88 signaling pathway in LPS-activated RAW 264.7 cells. Int Immunopharmacol. 2012; 14: 375–383.
Schmidt TJ, Brun R, Willuhn G, Khalid SA. Anti-trypanosomal activity of helenalin and some structurally related sesquiterpene lactones. Planta Med. 2002; 68: 750–751.
Stojanović-Radić Z, Comić Lj, Radulović N, Blagojević P, Denić M, Miltojević A, Rajković J, Mihajilov-Krstev T. Antistaphylococcal activity of Inula helenium L. root essential oil: eudesmane sesquiterpene lactones induce cell membrane damage. Eur J Clin Microbiol Infect Dis. 2012; 31: 1015–1025.
Xin XL, Ma XC, Liu KX, Han J, Wang BR, Guo DA. Microbial transformation of alantolactone by Mucor polymorphosporus. J Asian Nat Prod Res. 2008; 10: 933–937.
Tan RX, Tang HQ, Hu J, Shuai B. Lignans and sesquiterpene lactones from Artemisia sieversiana and Inula racemosa. Phytochemistry 1998; 49: 157–161.
Tripathi YB, Tripathi P, Upadhyay BN. Assessment of the adrenergic beta-blocking activity of Inula racemosa. J Ethnopharmacol. 1988; 23: 3–9.
Konishi T, Shimada Y, Nagao T, Okabe H, Konoshima T. Antiproliferative sesquiterpene lactones from the roots of Inula helenium. Biol Pharm Bull. 2002; 25: 1370–1372.
Pal HC, Sehar I, Bhushan S, Gupta BD, Saxena AK. Activation of caspases and poly (ADP-ribose) polymerase cleavage to induce apoptosis in leukemia HL-60 cells by Inula racemosa. Toxicol In Vitro. 2010; 24: 1599–1609.
Qiu J, Luo M, Wang J, Dong J, Li H, Leng B, Zhang Q, Dai X, Zhang Y, Niu X, Deng X. Isoalantolactone protects against Staphylococcus aureus pneumonia. FEMS Microbiol Lett. 2011; 324: 147–155.
Loscher W, Fassbender CP, Nolting B. The role of technical, biological and pharmacological factors in the laboratory evaluation of anticonvulsant drugs. II. Maximal electroshock seizure models. Epilepsy Res. 1991; 8: 79–94.
Litchfield JT, Wilcoxon F. A simplified method of evaluating dose-effect experiments. J Pharmacol Exp Ther. 1949; 96: 99–113.
Łuszczki JJ, Włodarczyk M, Gleńsk M, Marzęda E, Durmowicz D, Florek-Łuszczki M. Effects of alizarin, betulin, curcumin, diosmin, linalool, menthofuran, α-terpineol, theobromine, β-thujaplicin and vanillin against maximal electroshock-induced seizures in mice. J Pre- Clin Clin Res. 2013; 7: 5–8.
Stables JP, Kupferberg HJ. Chapter 16 – The NIH Anticonvulsant Drug Development (ADD) Program: preclinical anticonvulsant screening project. In: Avanzini G, Regesta G, Tanganelli P, Avoli M, eds. Molecular and cellular targets for anti-epileptic drugs. London, John Libbey, 1997. p. 191–198.
White HS, Woodhead JH, Wilcox KS, Stables JP, Kupferberg HJ, Wolf HH. Discovery and preclinical development of antiepileptic drugs. In: Levy RH, Mattson RH, Meldrum BS, Perucca E, eds. Antiepileptic drugs. 5th ed. Philadelphia, Lippincott Williams & Wilkins, 2002. p. 36–48.
Loscher W. Basic pharmacology of valproate: a review after 35 years of clinical use for the treatment of epilepsy. CNS Drugs 2002; 16: 669–694.